Compare Stocks: ZNTL, EYPT, CALT, and CRON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.15 +0.3%	$2.82	$2.28 ▼ $3.43	$1.16B	0.9	1.41 million shs	1.33 million shs
EYPT Eyepoint Pharmaceuticals	$4.87 -67.0%	$13.10	$3.95 ▼ $19.11	$1.27B	1.76	1.77 million shs	52.11 million shs
ZNTL Zentalis Pharmaceuticals	$3.70 +3.9%	$4.34	$1.21 ▼ $6.95	$255.15M	1.92	1.19 million shs	1.57 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	+0.32%	+5.00%	+12.90%	+20.69%	+32.91%
EYPT Eyepoint Pharmaceuticals	-66.98%	-62.74%	-63.38%	-58.80%	-56.09%
ZNTL Zentalis Pharmaceuticals	+3.93%	-10.84%	-27.59%	+4.52%	+132.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CRON Cronos Group	$3.15 +0.3%	$2.82	$2.28 ▼ $3.43	$1.16B	0.9	1.41 million shs	1.33 million shs
EYPT Eyepoint Pharmaceuticals	$4.87 -67.0%	$13.10	$3.95 ▼ $19.11	$1.27B	1.76	1.77 million shs	52.11 million shs
ZNTL Zentalis Pharmaceuticals	$3.70 +3.9%	$4.34	$1.21 ▼ $6.95	$255.15M	1.92	1.19 million shs	1.57 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	0.00%
CRON Cronos Group	+0.32%	+5.00%	+12.90%	+20.69%	+32.91%
EYPT Eyepoint Pharmaceuticals	-66.98%	-62.74%	-63.38%	-58.80%	-56.09%
ZNTL Zentalis Pharmaceuticals	+3.93%	-10.84%	-27.59%	+4.52%	+132.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CRON Cronos Group	2.40	Hold	$2.30	-26.98% Downside
EYPT Eyepoint Pharmaceuticals	2.73	Moderate Buy	$40.33	728.20% Upside
ZNTL Zentalis Pharmaceuticals	2.33	Hold	$6.75	82.43% Upside

Current Analyst Ratings Breakdown

Latest ZNTL, EYPT, CALT, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	EYPT Eyepoint Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00
8/17/2026	EYPT Eyepoint Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
8/17/2026	EYPT Eyepoint Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
8/17/2026	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/12/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/7/2026	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/6/2026	EYPT Eyepoint Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$47.00 ➝ $55.00
8/6/2026	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$30.00 ➝ $27.00
7/23/2026	ZNTL Zentalis Pharmaceuticals	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/17/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	ZNTL Zentalis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CRON Cronos Group	$179.09M	6.52	$0.01 per share	250.46	$3.00 per share	1.05
EYPT Eyepoint Pharmaceuticals	$31.37M	13.38	N/A	N/A	$3.70 per share	1.32
ZNTL Zentalis Pharmaceuticals	$67.43M	3.93	N/A	N/A	$2.99 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CRON Cronos Group	-$9.45M	$0.20	15.75	N/A	N/A	39.08%	4.85%	4.62%	11/5/2026 (Estimated)
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	N/A

Latest ZNTL, EYPT, CALT, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CRON Cronos Group	$0.01	$0.09	+$0.08	$0.09	$44.20 million	$53.01 million
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CRON Cronos Group	N/A	16.18	15.25
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
CRON Cronos Group	8.71%
EYPT Eyepoint Pharmaceuticals	99.41%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
CRON Cronos Group	7.80%
EYPT Eyepoint Pharmaceuticals	5.13%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	No Data
CRON Cronos Group	450	370.73 million	341.81 million	Optionable
EYPT Eyepoint Pharmaceuticals	120	86.21 million	81.79 million	Optionable
ZNTL Zentalis Pharmaceuticals	160	71.67 million	68.95 million	Optionable

ZNTL, EYPT, CALT, and CRON Headlines

Recent News About These Companies

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 17 at 7:21 PM | markets.businessinsider.com

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 17 at 4:01 PM | globenewswire.com

GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL

August 17 at 5:35 AM | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Hold" by Analysts

August 16 at 2:28 AM | americanbankingnews.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages

August 16 at 2:28 AM | marketbeat.com

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share

August 14, 2026 | msn.com

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

August 13, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

August 13, 2026 | globenewswire.com

HC Wainwright Analysts Decrease Earnings Estimates for ZNTL

August 11, 2026 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Rating Lowered to "Strong Sell" at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen

August 8, 2026 | marketbeat.com

Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL

August 7, 2026 | marketbeat.com

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

August 6, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

August 6, 2026 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Zentalis Pharmaceuticals (ZNTL) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

Rodman & Renshaw Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

July 23, 2026 | marketbeat.com

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?

July 20, 2026 | zacks.com

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

July 17, 2026 | globenewswire.com

Zentalis Pharmaceuticals Insider Trading Activity | NASDAQ:ZNTL | Benzinga

June 30, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, EYPT, CALT, and CRON Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/14/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Cronos Group NASDAQ:CRON

$3.15 +0.01 (+0.32%)

As of 08/17/2026 04:00 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$4.87 -9.88 (-66.98%)

As of 08/17/2026 04:00 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$3.70 +0.14 (+3.93%)

As of 08/17/2026 04:00 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZNTL, EYPT, CALT, and CRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZNTL, EYPT, CALT, and CRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZNTL, EYPT, CALT, and CRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, EYPT, CALT, and CRON Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Eyepoint Pharmaceuticals NASDAQ:EYPT

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZNTL, EYPT, CALT, and CRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZNTL, EYPT, CALT, and CRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZNTL, EYPT, CALT, and CRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL, EYPT, CALT, and CRON Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

Cronos Group NASDAQ:CRON

Eyepoint Pharmaceuticals NASDAQ:EYPT

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools